|
Apr 17
|
BeiGene to Announce First Quarter 2025 Financial Results on May 7
|
|
Apr 3
|
BeiGene halts ociperlimab amid poor Phase III trial predictions
|
|
Apr 3
|
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
|
|
Mar 31
|
Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value
|
|
Mar 31
|
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
|
|
Mar 21
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Mar 18
|
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
|
|
Feb 21
|
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
|
|
Feb 21
|
US Stocks Trading Below Estimated Value In February 2025
|
|
Feb 21
|
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
|
|
Feb 20
|
High Growth Tech Stocks in the United States to Watch
|
|
Feb 13
|
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
|
|
Feb 12
|
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?
|
|
Dec 30
|
BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment
|
|
Oct 10
|
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3
|
|
Oct 7
|
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
|
|
Aug 28
|
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
|
|
Aug 28
|
3 US Stocks That Could Be Trading At A Discount
|
|
Aug 28
|
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 27
|
FDA grants fast track status to BeiGene’s BGB-16673 for CLL/SLL
|